Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Neoadjuvant Chemoradiotherapy for MSS Locally Advanced Rectal Cancer
NCT06895577Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in rectal cancer, sponsored by Sun Yat-sen University. Planned start Jun 2025; status: withdrawn.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06895577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895577.